8-K: Calidi Biotherapeutics Secures $4.6 Million in Gross Proceeds from Warrant Exercises, Issues New Series H Warrants

Calidi Biotherapeutics has entered into an agreement with seven warrant holders to immediately exercise existing warrants at a reduced price, generating approximately $4.6 million in gross proceeds, and will issue new Series H warrants as an inducement.

Summary

• Calidi Biotherapeutics entered into an inducement offer letter agreement with 7 holders of existing Series A, B-1, C-1, D, E, and F warrants.
• These holders immediately exercised some or all of their existing warrants to purchase up to an aggregate of 6,595,000 shares of common stock.
• The exercise price for these warrants was reduced to $0.70 per share from previous prices of $1.52 (for Series A, B-1, C-1, D) and $1.13 (for Series E, F).
• The transaction is expected to generate approximately $4.6 million in gross proceeds for the company, before deducting placement agent fees and estimated offering expenses.
• In consideration for the immediate cash exercise, the company will issue new unregistered Series H common stock purchase warrants to purchase up to 6,595,000 shares of common stock.
• The new Series H warrants will have an exercise price of $0.70 per share, will be initially exercisable on January 10, 2026, and will have a term of 66 months from their issuance date.
• Ladenburg Thalmann & Co, Inc. acted as the exclusive placement agent, receiving an 8.0% fee of gross proceeds, a 1% management fee, and reimbursement for accountable legal expenses.
• The closing of these transactions is expected on July 10, 2025.
• Net proceeds are intended for general corporate purposes, including advancing clinical and pre-clinical programs, and for continuing operating expenses and working capital.

Sentiment

Score: 6

Explanation: The transaction successfully raised capital, which is crucial for a clinical-stage biotech. However, the significant reduction in exercise price for existing warrants and the issuance of new warrants at a low price indicate potential dilution and a need to incentivize funding, which tempers the positive impact. The fees paid to the placement agent also reduce the net proceeds.

Positives

• Secured approximately $4.6 million in gross proceeds, providing capital for general corporate purposes, clinical, and pre-clinical programs.
• Successful inducement of existing warrant holders to exercise, demonstrating investor confidence or willingness to participate in new offerings.
• Issuance of new warrants at the same exercise price ($0.70) as the reduced exercise price of the old warrants, potentially aligning future exercise incentives.

Negatives

• Significant reduction in exercise price for existing warrants (from $1.52 or $1.13 to $0.70), indicating a potential dilution for existing shareholders or a need to incentivize capital.
• Payment of substantial placement agent fees (8.0% of gross proceeds plus 1% management fee and legal expenses), reducing net proceeds.
• Issuance of new warrants (Series H) creates potential for future dilution upon their exercise.
• Company agreed to a 15-day lock-up on issuing new common stock or equivalents (with exceptions) and a 6-month restriction on variable rate financing, limiting financial flexibility in the short term.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early results of clinical trials do not necessarily predict final results and that one or more clinical outcomes may materially change.
• Risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Risk of dilution for existing shareholders due to the issuance of new warrants and the exercise of existing warrants at a reduced price.
• Potential for future stock price volatility due to the large number of shares underlying the new warrants becoming exercisable and potentially resold.
• Failure to deliver Warrant Shares by the Warrant Share Delivery Date could result in liquidated damages and 'Buy-In' compensation for the Holder.

Future Outlook

Calidi Biotherapeutics expects to use the net proceeds from these transactions for general corporate purposes, including advancing its clinical and pre-clinical programs and for continuing operating expenses and working capital. The company has agreed to file a registration statement for the resale of shares underlying the new Series H warrants within 15 days of closing and aims for it to be effective within 45 to 75 days. The company also faces risks related to raising sufficient capital for clinical trials, the unpredictability of clinical trial results, and the uncertainty of FDA approval for its therapeutic candidates.

Management Comments

• Calidi Biotherapeutics, a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A, Series B-1, Series C-1, Series D, Series E and Series F Warrants to purchase up to an aggregate of 6,595,000 shares of the Company's common stock at a reduced exercise price of $0.70.
• The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.6 million, prior to deducting placement agent fees and estimated offering expenses.
• The Company intends to use the net proceeds from this offering to advance its clinical and pre-clinical programs and for continuing operating expenses and working capital.

Industry Context

This transaction is typical for clinical-stage biotechnology companies like Calidi Biotherapeutics, which often rely on capital raises, including warrant exercises, to fund extensive and costly research, development, and clinical trial programs. The use of inducement offers with reduced exercise prices and the issuance of new warrants is a common strategy to secure immediate funding while maintaining investor interest, albeit at the cost of potential future dilution. The focus on advancing clinical and pre-clinical programs aligns with the industry's emphasis on pipeline development to achieve regulatory approvals and commercialization.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against.
• The practice of offering inducement exercises at reduced prices and issuing new warrants is a common financing mechanism in the biotechnology sector, particularly for clinical-stage companies that require significant capital for R&D without immediate revenue streams.
• The 8% placement agent fee and 1% management fee are within the typical range for such transactions, which can vary based on the size of the raise, market conditions, and the perceived risk of the company.
• The terms of the new warrants (6-month initial exercisability, 5.5-year term, $0.70 exercise price) are specific to this company's financing needs and market valuation, and would require a detailed analysis of comparable biotech warrant terms to assess their competitiveness.

Stakeholder Impact

• Shareholders: Potential for dilution due to the exercise of existing warrants at a reduced price and the future exercise of newly issued Series H warrants. The capital raise provides funding for company operations and programs, which could benefit long-term value if successful.
• Warrant Holders (Participating): Benefit from the reduced exercise price on their existing warrants and receive new Series H warrants as an inducement, offering further potential upside.
• Company Operations: The $4.6 million in gross proceeds (net of fees) provides crucial capital for advancing clinical and pre-clinical programs, supporting ongoing operations, and working capital.
• Placement Agent (Ladenburg Thalmann & Co, Inc.): Benefits from significant fees (8% of gross proceeds + 1% management fee + legal expenses reimbursement) for facilitating the transaction.

Next Steps

• Closing of the transactions is expected on July 10, 2025.
• Company to file a Current Report on Form 8-K disclosing material terms of the transactions on or before 9:00 a.m. (New York City time) on July 10, 2025.
• Company to file a registration statement on Form S-1 for the resale of common stock underlying the new Series H Warrants within 15 calendar days of the Closing Date.
• Company to use best efforts to have the resale registration statement declared effective by the SEC within 45 days (or 75 days if SEC reviews).
• New Series H Warrants will become initially exercisable on January 10, 2026.
• Company will not issue or announce issuance of common stock or equivalents, or file registration statements (except S-8) for 15 days following closing.
• Company will not enter into variable rate financing for 6 months following closing (with exceptions).

Key Dates

Recommendation

Keywords

Calidi Biotherapeutics, CLDI, Warrant Exercise, Capital Raise, SEC Filing, 8-K, Biotechnology, Clinical-stage, Oncology, Genetic Medicines, Series H Warrants, Ladenburg Thalmann, Dilution, Private Placement, SEC Registration, Redtail platform